Novel TRPV1 Agonist Prodrugs for Treating Pain
Our pipeline consists of innovative non-opioid product candidates focused on managing pain from acute and chronic conditions where current options have resulted in significant unmet medical need. Our lead product candidate, CA-008, is a potential first-of-class single injectable prodrug of capsaicin that is designed to treat acute post-surgical pain.
We are also actively developing a second product candidate, CA-011, a potential best-in-class single injectable prodrug of capsaicin specifically designed to treat chronic pain associated from moderate to severe osteoarthritis.
In addition, we have a third product candidate, CA-024, which is specifically designed to treat intractable cancer pain.
Our goal is to develop each of our products with patients’ needs at the center of our focus, and to deliver products with best-in-class therapeutic potential.